Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 63629-4698

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 63629-4698). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Divalproex Fig1)

A line graph comparing the percentage reduction in CPS rate between Divalproex Sodium Delayed-Release Tablets and placebo across a percentage of patients. The graph shows improvement and worsening relative to no change, with the Divalproex sodium treatment generally demonstrating greater improvement than placebo.*

FDA Label Image

Figure 2 (Divalproex Fig2)

A graph plotting the percentage of patients on the x-axis against the percent reduction in CPS rate on the y-axis. It compares high dose and low dose Divalproex Sodium delayed-release tablets, showing the rate of improvement or worsening in patients.*

FDA Label Image

Figure 3. Mean Reduction In 4-week Migraine Headache Rates (Divalproex Fig3)

A bar chart comparing the effect of placebo and Divalproex Sodium extended-release tablets. The vertical axis ranges from 0 to 1.2, showing higher value for Divalproex Sodium extended-release tablets (around 1.2) compared to placebo (around 0.6). A statistical significance marker indicates p=0.006.*

FDA Label Image

Structure (Divalproex Str)

Chemical structure of Divalproex sodium showing the molecular composition with carbon, hydrogen, oxygen atoms, and sodium ion, indicating the repeating unit of the polymer.*

FDA Label Image

Lbl636294698

Label for Divalproex Sodium 500 mg extended-release oral tablets by Bryant Ranch Prepack. The label compares the product to Depakote 500 mg ER tablets by Aurobindo Pharma. It includes storage instructions at 20°-25°C (68°-77°F) and directs to keep the container tightly closed. The package size is 60 tablets and includes a barcode and NDC 63629-4698-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.